Proteostasis Therapeutics (PTI) Stock Rating Upgraded by ValuEngine

Proteostasis Therapeutics (NASDAQ:PTI) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Monday.

PTI has been the subject of a number of other research reports. Zacks Investment Research raised shares of Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a research report on Tuesday, March 20th. Royal Bank of Canada initiated coverage on shares of Proteostasis Therapeutics in a research report on Friday, March 9th. They issued an “outperform” rating and a $11.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Proteostasis Therapeutics has an average rating of “Buy” and a consensus target price of $13.45.

Shares of NASDAQ:PTI opened at $5.01 on Monday. Proteostasis Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $8.61. The stock has a market cap of $181.03 million, a P/E ratio of -2.14 and a beta of 4.14.

Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings data on Wednesday, March 14th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.14. Proteostasis Therapeutics had a negative net margin of 1,112.75% and a negative return on equity of 105.53%. The business had revenue of $1.62 million during the quarter, compared to the consensus estimate of $1.58 million. research analysts expect that Proteostasis Therapeutics will post -2.11 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of PTI. Trexquant Investment LP bought a new position in Proteostasis Therapeutics in the 1st quarter worth about $149,000. Jefferies Group LLC bought a new position in Proteostasis Therapeutics in the 4th quarter worth about $175,000. Jane Street Group LLC bought a new position in Proteostasis Therapeutics in the 4th quarter worth about $203,000. Goldman Sachs Group Inc. bought a new position in Proteostasis Therapeutics in the 4th quarter worth about $354,000. Finally, Sectoral Asset Management Inc bought a new position in Proteostasis Therapeutics in the 4th quarter worth about $1,749,000. Hedge funds and other institutional investors own 68.59% of the company’s stock.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply